Comparison Chart Oramed Pharmaceuticals Inc.
Stocks
ORMP
US68403P2039
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:01 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 4.670 USD | -0.43% |
|
-1.06% | +63.86% |
| 09-20 | Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to S&P Global BMI Index | CI |
| 08-31 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. | Other Biotechnology & Medical Research | -0.43% | -1.06% | +63.86% | +76.89% | -78.75% | 195M |  |  | |
- Stock Market
- Stocks
- ORMP Stock
- Charts Oramed Pharmaceuticals Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
